|Systematic (IUPAC) name|
|Legal status||℞ Prescription only|
|Mol. mass||370.482 g/mol|
Nomegestrol acetate (INN; Lutenyl), or 19-normegestrol acetate, is a steroidal progestin with additional antigonadotropic effects which was introduced in 1986 and is used as a hormonal contraceptive. Unlike many other steroidal progestogens, it is selective for the progesterone receptor, lacking any significant affinity for other steroid receptors such as the androgen, estrogen, glucocorticoid, and mineralocorticoid receptors. As a result, it does not possess any androgenic, estrogenic, glucocorticoid, or mineralocorticoid effects. However, at sufficiently high doses it does have potent antiestrogenic and antiandrogenic effects due to its progesterone receptor-mediated antigonadotropic properties.
See also 
- F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1445. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.
- Jamin C, Batallan A, Madelenat P (January 2003). "[Antigonadotropic effects of a 19-nor-progesterone derivative: the example of nomegestrol acetate]". Gynécologie, Obstétrique & Fertilité (in French) 31 (1): 70–81. PMID 12659788.
- Lello S (March 2010). "Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy". Drugs 70 (5): 541–59. doi:10.2165/11532130-000000000-00000. PMID 20329803.
- Paris J, Thévenot R, Bonnet P, Granero M (1983). "The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative". Arzneimittel-Forschung 33 (5): 710–5. PMID 6683550.
- European Medicines Agency: Zoely
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|